In 2020, a North American team showed that α-particles combined with daratumumab reduce tumor growth in an animal model [105], but due to the possible down-modulation of CD38 on the surface of refractory cells, novel deep epitopes targetable by nanobodies have been recently investigated. Here, CD38 is linked to neoplasm.